

AVP: All Vasopressin Podcast References

Special Guests: Gretchen Sacha, PharmD, BCCCP
Seth Bauer, PharmD, FCCM, FCCP, BCCCP

Guidelines

Evans L, Rhodes A, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. *Crit Care Med*. 2021 Nov 1;49(11):e1063-e1143. <https://pubmed.ncbi.nlm.nih.gov/34605781/>

Review Articles

Sacha GL, Bauer SR, Lat I. Vasoactive Agent Use in Septic Shock: Beyond First-Line Recommendations. *Pharmacotherapy*. 2019 Mar;39(3):369-381. <https://pubmed.ncbi.nlm.nih.gov/30644586/>

Bauer SR, Sacha GL, Lam SW. Safe Use of Vasopressin and Angiotensin II for Patients with Circulatory Shock. *Pharmacotherapy*. 2018 Aug;38(8):851-861. <https://pubmed.ncbi.nlm.nih.gov/29878459/>

Articles Referenced

VASST Investigators. Vasopressin versus norepinephrine infusion in patients with septic shock. *N Engl J Med*. 2008 Feb 28;358(9):877-87. <https://pubmed.ncbi.nlm.nih.gov/18305265/>

VANISH Investigators. Effect of Early Vasopressin vs Norepinephrine on Kidney Failure in Patients With Septic Shock: The VANISH Randomized Clinical Trial. *JAMA*. 2016 Aug 2;316(5):509-18. <https://pubmed.ncbi.nlm.nih.gov/27483065/>

Dünser MW, Mayr AJ, Ulmer H, et al. Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study. *Circulation*. 2003 May 13;107(18):2313-9. <https://pubmed.ncbi.nlm.nih.gov/12732600/>

Torgersen C, Dünser MW, Wenzel V, et al. Comparing two different arginine vasopressin doses in advanced vasodilatory shock: a randomized, controlled, open-label trial. *Intensive Care Med*. 2010 Jan;36(1):57-65. <https://pubmed.ncbi.nlm.nih.gov/19756505/>

Hajjar LA, Vincent JL, Barbosa Gomes Galas FR, et al. Vasopressin versus Norepinephrine in Patients with Vasoplegic Shock after Cardiac Surgery: The VANCS Randomized Controlled Trial. *Anesthesiology*. 2017 Jan;126(1):85-93. <https://pubmed.ncbi.nlm.nih.gov/27841822/>

Hajjar LA, Zambolim C, Belletti A, et al. Vasopressin Versus Norepinephrine for the Management of Septic Shock in Cancer Patients: The VANCS II Randomized Clinical Trial. *Crit Care Med*. 2019 Dec;47(12):1743-1750. <https://pubmed.ncbi.nlm.nih.gov/31609774/>

Oliveira S, Dessa F, Rocha C, Oliveira F. Early Vasopressin Application in Shock study. *Crit Care*. 2014;18(Suppl 1):P158. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4068773/>

Sacha GL, Lam SW, Wang L, Duggal A, Reddy AJ, Bauer SR. Association of Catecholamine Dose, Lactate, and Shock Duration at Vasopressin Initiation With Mortality in Patients With Septic Shock. *Crit Care Med*. 2022 Apr 1;50(4):614-623. <https://pubmed.ncbi.nlm.nih.gov/34582425/>

Bauer SR, Sacha GL, Lam SW, et al. Hemodynamic Response to Vasopressin Dosage of 0.03 Units/Min vs. 0.04 Units/Min in Patients With Septic Shock. *J Intensive Care Med*. 2022 Jan;37(1):92-99. <https://pubmed.ncbi.nlm.nih.gov/33251906/>

Torbic H, Sacha GL, Bauer SR, Lam SW. Body Mass's Impact on Response to Fixed-Dose Vasopressin in Patients With Septic Shock. *Shock*. 2018 Oct;50(4):388-394. <https://pubmed.ncbi.nlm.nih.gov/29240642/>

Dünser MW, Mayr AJ, Tür A, et al. Ischemic skin lesions as a complication of continuous vasopressin infusion in catecholamine-resistant vasodilatory shock: incidence and risk factors. *Crit Care Med*. 2003 May;31(5):1394-8. <https://pubmed.ncbi.nlm.nih.gov/12771608/>

McIntyre WF, Um KJ, Alhazzani W, et al. Association of Vasopressin Plus Catecholamine Vasopressors vs Catecholamines Alone With Atrial Fibrillation in Patients With Distributive Shock: A Systematic Review and Meta-analysis. *JAMA*. 2018 May 8;319(18):1889-1900. <https://pubmed.ncbi.nlm.nih.gov/29801010/>

Sacha GL, Lam SW, Duggal A, et al. Predictors of response to fixed-dose vasopressin in adult patients with septic shock. *Ann Intensive Care*. 2018 Mar 6;8(1):35. <https://pubmed.ncbi.nlm.nih.gov/29511951/>

Scheibner A, Betthausen KD, Bewley AF, et al. Machine learning to predict vasopressin responsiveness in patients with septic shock. *Pharmacotherapy*. 2022 Jun;42(6):460-471. <https://pubmed.ncbi.nlm.nih.gov/35426141/>

Yerke JR, Sacha GL, Scheraga RG, et al. Vasopressin Plasma Concentrations Are Not Associated with Hemodynamic Response to Exogenous Vasopressin for Septic Shock. *Pharmacotherapy*. 2020 Jan;40(1):33-39. <https://pubmed.ncbi.nlm.nih.gov/31705703/>

Nick Peters, PharmD

Pharmacy To Dose: The Critical Care Podcast

AVP: All Vasopressin Podcast References

Gordon AC, Russell JA, Walley KR, et al. The effects of vasopressin on acute kidney injury in septic shock. *Intensive Care Med*. 2010 Jan;36(1):83-91.

<https://pubmed.ncbi.nlm.nih.gov/19841897/>

Ammar MA, Ammar AA, Wieruszewski PM, et al. Timing of vasoactive agents and corticosteroid initiation in septic shock. *Ann Intensive Care*. 2022 May 30;12(1):47.

<https://pubmed.ncbi.nlm.nih.gov/35644899/>

Sacha GL, Lam SW, Duggal A, et al. Hypotension Risk Based on Vasoactive Agent Discontinuation Order in Patients in the Recovery Phase of Septic Shock. *Pharmacotherapy*. 2018 Mar;38(3):319-326. <https://pubmed.ncbi.nlm.nih.gov/29328496/>

Jeon K, Song JU, Chung CR, et al. Incidence of hypotension according to the discontinuation order of vasopressors in the management of septic shock: a prospective randomized trial (DOVSS). *Crit Care*. 2018 May 21;22(1):131. <https://pubmed.ncbi.nlm.nih.gov/29784057/>

Hammond DA, Sacha GL, Bissell BD, et al. Effects of Norepinephrine and Vasopressin Discontinuation Order in the Recovery Phase of Septic Shock: A Systematic Review and Individual Patient Data Meta-Analysis. *Pharmacotherapy*. 2019 May;39(5):544-552.

<https://pubmed.ncbi.nlm.nih.gov/30893494/>

Sacha GL, Kiser TH, Wright GC, et al. Association Between Vasopressin Rebranding and Utilization in Patients With Septic Shock. *Crit Care Med*. 2022 Apr 1;50(4):644-654.

<https://pubmed.ncbi.nlm.nih.gov/34605778/>

Lam SW, Barreto EF, Scott R, et al. Cost-effectiveness of second-line vasopressors for the treatment of septic shock. *J Crit Care*. 2020 Feb;55:48-55.

<https://pubmed.ncbi.nlm.nih.gov/31706118/>

Dugar S, Siuba MT, Sacha GL, et al. Echocardiographic profiles and hemodynamic response after vasopressin initiation in septic shock: A cross-sectional study. *J Crit Care*. 2023 Aug;76:154298.

<https://pubmed.ncbi.nlm.nih.gov/37030157/>

Nguyen M, Berthoud V, Rizk A, et al. Real life use of vasopressin in patients with cardiogenic shock: a retrospective cohort analysis. *Crit Care*. 2023 Jul 19;27(1):291.

<https://pubmed.ncbi.nlm.nih.gov/37468928/>